- Home
- LQDA vs APLS Comparison
LQDA vs APLS Comparison
Compare LQDA & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LQDA
- APLS
- Stock Information
- Founded
- LQDA 2004
- APLS 2009
- Country
- LQDA United States
- APLS United States
- Employees
- LQDA N/A
- APLS N/A
- Industry
- LQDA Biotechnology: Pharmaceutical Preparations
- APLS Biotechnology: Pharmaceutical Preparations
- Sector
- LQDA Health Care
- APLS Health Care
- Exchange
- LQDA Nasdaq
- APLS Nasdaq
- Market Cap
- LQDA 2.5B
- APLS 2.9B
- IPO Year
- LQDA 2018
- APLS 2017
- Fundamental
- Price
- LQDA $32.15
- APLS $21.08
- Analyst Decision
- LQDA Strong Buy
- APLS Buy
- Analyst Count
- LQDA 10
- APLS 19
- Target Price
- LQDA $37.40
- APLS $33.11
- AVG Volume (30 Days)
- LQDA 2.7M
- APLS 3.3M
- Earning Date
- LQDA 11-03-2025
- APLS 10-30-2025
- Dividend Yield
- LQDA N/A
- APLS N/A
- EPS Growth
- LQDA N/A
- APLS N/A
- EPS
- LQDA N/A
- APLS 0.36
- Revenue
- LQDA $69,216,000.00
- APLS $1,016,397,000.00
- Revenue This Year
- LQDA $424.31
- APLS $25.39
- Revenue Next Year
- LQDA $359.32
- APLS N/A
- P/E Ratio
- LQDA N/A
- APLS $58.64
- Revenue Growth
- LQDA 343.41
- APLS 42.11
- 52 Week Low
- LQDA $10.37
- APLS $16.10
- 52 Week High
- LQDA $32.41
- APLS $35.72
- Technical
- Relative Strength Index (RSI)
- LQDA 70.67
- APLS 46.73
- Support Level
- LQDA $27.76
- APLS $19.40
- Resistance Level
- LQDA $30.50
- APLS $20.70
- Average True Range (ATR)
- LQDA 1.85
- APLS 0.74
- MACD
- LQDA 0.36
- APLS 0.17
- Stochastic Oscillator
- LQDA 98.23
- APLS 94.55
About LQDA Liquidia Corporation
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.